UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib

Cancer Chemotherapy and Pharmacology

Volumn 65, Issue 1, 2009, Pages 1-4

  Meza Junco, Judith ^a   Chu, Quincy S C ^a   Christensen, Olaf ^b   Rajagopalan, Prabhu ^b   Das, Soma ^c   Stefanyschyn, Ruslan ^a   Sawyer, Michael B ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Bayer HealthCare Pharmaceuticals Inc   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

Hepatocellular carcinoma; Hyperbilirubinemia; Sorafenib; UGT1A1 polymorphism

Indexed keywords

BILIRUBIN; BILIRUBIN GLUCURONIDE; CYCLOPHOSPHAMIDE; DOXORUBICIN; GLUCURONOSYLTRANSFERASE 1A1; SORAFENIB;

ADULT; ALLELE; BILIRUBIN BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CHEMOEMBOLIZATION; DNA POLYMORPHISM; DRUG DOSE REDUCTION; DRUG TOLERABILITY; GENOTYPE; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; PRIORITY JOURNAL; SHORT SURVEY; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS, PHASE I AS TOPIC; CYCLOPHOSPHAMIDE; DOXORUBICIN; GLUCURONOSYLTRANSFERASE; HUMANS; HYPERBILIRUBINEMIA; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PYRIDINES;

EID: 68249135542     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1096-4     Document Type: Short Survey

References (24)

1. A Cheng Y Kang Z Chen, et al. 2008 Randomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma J Clin Oncol 26 15s a4509
2. JM Llovet S Ricci V Mazzaferro, et al. 2008 Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 378 390 18650514 10.1056/NEJMoa0708857 1:CAS:528:DC%2BD1cXovFWjsL8%3D
3. D Strumberg JW Clark A Awada, et al. 2007 Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors Oncologist 12 426 437 17470685 10.1634/theoncologist.12-4-426 1:CAS:528:DC%2BD2sXmtlSitrs%3D (Pubitemid 46698720)
4. G Monaghan M Ryan R Seddon R Hume B Burchell 1996 Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome Lancet 347 578 581 8596320 10.1016/S0140-6736(96)91273-8 1:CAS:528: DyaK28XitVGrtrc%3D (Pubitemid 26070740)
5. PG Wells PI Mackenzie JR Chowdhury, et al. 2004 Glucuronidation and the UDP-glucuronosyltransferases in health and disease Drug Metab Dispos 32 281 290 14977861 10.1124/dmd.32.3.281 1:CAS:528:DC%2BD2cXhslOks7o%3D (Pubitemid 38263885)
6. TM Bosch I Meijerman JH Beijnen 2006 Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer Clin Pharmacokinet 45 253 285 16509759 10.2165/00003088- 200645030-00003 1:CAS:528:DC%2BD28XjsFOksb0%3D (Pubitemid 43327492)
7. CP Strassburg 2008 Pharmacogenetics of Gilbert's syndrome Pharmacogenomics 9 703 715 18518849 10.2217/14622416.9.6.703 1:CAS:528:DC%2BD1cXmslyjtbo%3D
8. AS Rudenski DJ Halsall 1998 Genetic testing for Gilbert's syndrome: how useful is it in determining the cause of jaundice? Clin Chem 44 8 Pt 1 1604 1609 9702945 1:CAS:528:DyaK1cXltleltLw%3D
9. GM Hirschfield GJ Alexander 2006 Gilbert's syndrome: an overview for clinical biochemists Ann Clin Biochem 43 Pt 5 340 343 17022875 10.1258/000456306778520034 1:CAS:528:DC%2BD28XhtFCht7nE (Pubitemid 44526531)
10. B Burchell R Hume 1999 Molecular genetic basis of Gilbert's syndrome J Gastroenterol Hepatol 14 960 966 10530490 10.1046/j.1440-1746.1999.01984.x 1:CAS:528:DyaK1MXntVerur8%3D (Pubitemid 29487290)
11. P Biason S Masier G Toffoli 2008 UGT1A1*28 and other UGT1A polymorphisms as determinants of irinotecan toxicity J Chemother 20 18 65
12. Z Wen MN Tallman SY Ali, et al. 2007 UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics Drug Metab Dispos 35 371 380 17151191 10.1124/dmd.106.012732 1:CAS:528:DC%2BD2sXisl2itLc%3D (Pubitemid 46333899)
13. C Lathia J Lettieri F Cihon, et al. 2006 Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics Cancer Chemother Pharmacol 57 685 692 16133532 10.1007/s00280-005-0068-6 1:CAS:528:DC%2BD28Xjs1KktLk%3D
14. S Wilhelm DS Chien 2002 BAY 43-9006: preclinical data Curr Pharm Des 8 2255 2257 12369853 10.2174/1381612023393026 1:CAS:528:DC%2BD38XnvVGntrs%3D (Pubitemid 35189898)
15. Bayer NEXAVAR® product monograph. Toronto, Ontario, Bayer Inc, 2007
16. GK Abou-Alfa D Amadori A Santoro, et al. 2008 Is sorafenib (S) safe and effective in patients (pts) with hepatocellular carcinoma (HCC) and Child-Pugh B (CPB) cirrhosis? J Clin Oncol 26 15S a4518
17. B Escudier T Eisen WM Stadler, et al. 2007 Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 125 134 17215530 10.1056/NEJMoa060655 1:CAS:528:DC%2BD2sXksVKitg%3D%3D (Pubitemid 46089673)
18. MJ Ratain T Eisen WM Stadler, et al. 2006 Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 24 2505 2512 16636341 10.1200/JCO.2005.03.6723 1:CAS:528:DC%2BD28XmtVOmtrk%3D (Pubitemid 46630627)
19. C Merkel R Marin P Angeli, et al. 2004 A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis Gastroenterology 127 476 484 15300580 10.1053/j.gastro.2004.05.004 1:CAS:528:DC%2BD2cXntlyjs7w%3D (Pubitemid 39091896)
20. LJ Goldstein A O'Neill JA Sparano, et al. 2008 Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197 J Clin Oncol 26 4092 4099 18678836 10.1200/JCO.2008.16.7841 1:CAS:528:DC%2BD1cXhtFKisLfJ
21. LF Hutchins SJ Green PM Ravdin, et al. 2005 Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102 J Clin Oncol 23 8313 8321 16293862 10.1200/JCO.2005.08.071 1:CAS:528: DC%2BD2MXhtlWhtrjK (Pubitemid 46260226)
22. Katsumata N, Watanabe T, Minami H et al (2009) Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan Clinical Oncology Group trial. Ann Oncol (Advance Access published March 2)
23. MC Liu GD Demetri DA Berry, et al. 2008 Cancer and Leukemia Group B. Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel Cancer Treat Rev 34 223 230 18234424 10.1016/j.ctrv.2007.11.004 1:CAS:528:DC%2BD1cXls12qurg%3D
24. P Rastogi SJ Anderson HD Bear, et al. 2008 Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27 J Clin Oncol 26 778 785 18258986 10.1200/JCO.2007.15.0235 (Pubitemid 351264391)